An organic acid is an organic compound that contains an acidic functional group — most commonly a carboxylic acid (–COOH) or a closely related derivative such as an ester, lactone, or carbamate. The grouping is purely structural-chemical: members are classified by the presence of an acid or acid-derived group, not by any shared pharmacological mechanism or target.
The psychoactive substances grouped here span three structural sub-families: a free short-chain carboxylic acid (GHB), its cyclic ester (GBL), and a nitrogen-bearing dicarbamate (carisoprodol). Each falls into a distinct child sub-class — butyric acid, lactone, and nitrogenous organic acid respectively — and they share no common scaffold beyond the broad organic-acid lineage. Despite this chemical diversity, all three are central nervous system depressants.
Clinically and recreationally, members of this class are used for sedation, hypnosis, anxiolysis, and muscle relaxation. Sodium oxybate (a GHB salt) is approved for narcolepsy with cataplexy, carisoprodol is prescribed short-term for musculoskeletal pain, and GBL is largely industrial and unapproved for human use. At higher exposures, all three produce deep sedation, amnesia, and dose-dependent suppression of breathing.[1]
Pharmacology
The three members reach CNS depression by chemically unrelated routes, but each augments inhibitory GABAergic neurotransmission. The shared outcome — net suppression of brainstem and cortical excitability — is what gives this otherwise heterogeneous class a single functional signature.[2]
| Mechanism | Representative members | How it reaches the shared endpoint |
|---|---|---|
| GABAB partial agonism and GHB-receptor agonism | GHB; GBL after hydrolysis to GHB | Activates inhibitory metabotropic signalling, suppressing arousal and dose-dependently depressing respiratory rate |
| GABAA direct activation and barbiturate-like allosteric potentiation | Carisoprodol (and its long-lived active metabolite) | Increases chloride conductance through GABAA channels, hyperpolarizing neurons |
GBL is itself inactive at GHB and GABAB receptors; serum lactonase enzymes convert it to GHB within minutes of absorption, after which it acts entirely through GHB's receptor targets.[3] Its higher lipophilicity accelerates absorption and raises peak GHB concentrations relative to an equivalent dose of GHB itself.[4]
Carisoprodol's GABAA effects are blocked by barbiturate-site antagonists but not by flumazenil, distinguishing its mechanism from the benzodiazepines;[5] the parent compound is also hepatically metabolised to a long-lived carbamate metabolite that itself acts at GABAA, adding a second GABAergic component to its pharmacodynamic profile.[6]
The endpoint matters more than the route. Whichever receptor system each member engages, the result is the same brainstem-mediated suppression of respiratory drive that defines the acute danger of the class.[7]
Substances
The three members illustrate the chemical breadth of the class — a free carboxylic acid, its cyclic ester, and a synthetic dicarbamate — while sharing a convergent depressant profile.
| Member | Sub-class | Role / distinctive feature |
|---|---|---|
| GHB | Butyric acid (short-chain hydroxylated carboxylic acid) | Endogenous GABA metabolite; approved as sodium oxybate for narcolepsy with cataplexy; rapid onset, short duration |
| GBL | Lactone (cyclic ester of GHB) | Industrial solvent with no approved human medical role; converted to GHB after ingestion, with faster onset and higher peak GHB than an equivalent oral dose of GHB |
| Carisoprodol | Nitrogenous organic acid (propanediol dicarbamate) | Prescription skeletal muscle relaxant for short-term musculoskeletal pain; chemically related to older propanediol carbamates; longer-acting; controlled in the United States and withdrawn from several European markets |
These three members differ widely in their chemistry, clinical role, and pharmacokinetics, but each contributes GABAergic depressant load when taken alone or in combination with other depressants.
Subjective Effects
Across the class the subjective trajectory tracks deepening GABAergic inhibition as exposure rises.[1]
| Exposure | Characteristic effects |
|---|---|
| Low | Mild euphoria, anxiolysis, muscle relaxation, lowered inhibition, and an alcohol-like disinhibitory feel |
| Moderate–high | Deepening sedation, slurred speech, ataxia, anterograde amnesia, and significant impairment of motor control and judgement |
| High | Stupor, loss of protective airway reflexes, respiratory depression, and coma; for GHB and GBL, an abrupt loss of consciousness and equally abrupt return is a clinical hallmark |
Because the same physiological axis drives both the sought effects and the dangerous ones, the margin between heavy sedation and life-threatening depression narrows quickly as exposure rises. The margin is particularly narrow for GHB and GBL, whose dose-response curves are steep and whose euphorigenic and incapacitating ranges sit close together; the inconsistent potency of illicit GBL preparations compounds this for recreational users.[4]
Safety
Risk profile
The defining acute danger of this class is dose-dependent CNS and respiratory depression, with no specific antidote available for the GHB-family members. Combining any class member with alcohol, opioids, benzodiazepines, or other depressants sharply raises the risk of fatal respiratory failure, and polysubstance involvement is one of the most consistent findings in depressant-related fatalities.
GHB and GBL produce respiratory depression through GABAB receptor activation, which dose-dependently suppresses respiratory rate; in animal studies the depression is completely reversed by GABAB antagonism, confirming a single mechanistic target.[7] Treatment of overdose is supportive: no clinically available GABAB antagonist exists for emergency use, and naloxone does not reverse GHB, GBL, or carisoprodol toxicity. Carisoprodol overdose most often involves polysubstance combinations, in which its GABAA modulation and long-lived active metabolite stack with other depressants.[5]
The rapid onset, dense amnesia, and near-tastelessness of GHB and GBL have given them a documented role in drug-facilitated sexual assault.[1] All three members impair motor coordination and judgement to an extent that makes operating vehicles or heavy machinery acutely dangerous.
Tolerance & dependence
Regular use of any member produces tolerance and physical dependence. GHB and GBL tolerance develops rapidly with heavy daily dosing; users escalate dose and shorten dosing intervals to maintain effect, and dependence can develop within weeks.[8] Carisoprodol tolerance develops within days in preclinical models, and precipitated-withdrawal studies confirm a GABAA-mediated physical dependence substrate.[9] Because GBL is a prodrug of GHB, cross-tolerance between the two is essentially complete; cross-tolerance with other GABAergic depressants is pharmacologically plausible across the class.
Carisoprodol withdrawal resembles meprobamate or benzodiazepine withdrawal and can include hallucinations and delusions in severe cases.[6] People physically dependent on any of these substances should not stop abruptly without clinical supervision.
Recovery
Dependence on any member of this class is treatable, but it is medically serious and detoxification should not be attempted alone. GHB and GBL detoxification typically requires inpatient management with high-dose benzodiazepines, escalating to barbiturates or intensive sedation in refractory cases. Carisoprodol withdrawal can often be managed with a supervised benzodiazepine taper in outpatient settings for milder dependence. A clinician or a specialist withdrawal-management service can assess severity and structure a safe taper.Recovery resources, crisis lines, and support pathways → View all
Sub-classes
Members
references
- [1]^abcSchep LJ, Knudsen K, Slaughter RJ, Vale JA, Megarbane B (2012) The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol — Clinical Toxicology doi:10.3109/15563650.2012.702218
- [2]^Giorgetti, A. and Busardò, F.P. and Giorgetti, R. (2022) Toxicological characterization of GHB as a performance-enhancing drug — Frontiers in Psychiatry doi:10.3389/fpsyt.2022.846983
- [3]^Carter, L.P. and Chen, W. and Wu, H. and Mehta, A.K. and Hernandez, R.J. and Ticku, M.K. and Coop, A. and Koek, W. and France, C.P. (2009) Behavioral effects and pharmacokinetics of gamma-hydroxybutyrate (GHB) precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) in baboons — Psychopharmacology doi:10.1007/s00213-009-1477-8
- [4]^abBusardò, F.P. and Gottardi, M. and Tini, A. and Minutillo, A. and Sirignano, A. and Marinelli, E. and Zaami, S. (2018) Replacing GHB with GBL in recreational settings: a new trend in chemsex — Current Drug Metabolism doi:10.2174/1389200219666180925090834
- [5]^abGonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ (2009) Carisoprodol-Mediated Modulation of GABAA Receptors: In Vitro and in Vivo Studies — Journal of Pharmacology and Experimental Therapeutics doi:10.1124/jpet.109.151142
- [6]